43 Grants (Page 1 of 2)
2024
Hypoxia's role in regulating stressed hematopoietic stem cells
Kapur, Reuben and Tran, Ngoc T
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 1R01DK139505-01), $684,735USD, 2024-03-01 -- 2027-12-31
2022
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors
Kapur, Reuben and Sintim, Herman O
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA267978-01), $495,845USD, 2022-05-10 -- 2027-04-30
2021
Novel drug to treat poor prognosis AML
Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA263239-01), $234,662USD, 2021-07-02 -- 2023-06-30
 
Role of p21 activated kinase in Leukemogenesis
Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 2R01CA173852-06), $369,310USD, 2014-05-01 -- 2026-07-31
 
Role of Shp2 in FLT3-ITD induced leukemogenesis
Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA134777-08), $374,063USD, 2011-04-01 -- 2024-01-31
2020
Role of Shp2 in FLT3-ITD induced leukemogenesis
Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA134777-07), $374,063USD, 2011-04-01 -- 2024-01-31
 
Targeting Novel Pathways in JMML
Kapur, Reuben
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 5R01HL146137-02), $507,815USD, 2019-01-15 -- 2022-12-31
2019
Hyperglycemia mediated myeloproliferative disease
Kapur, Reuben
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 1R01HL140961-01A1), $586,415USD, 04/01/2019 -- 03/31/2023
 
Role of Shp2 in FLT3-ITD induced leukemogenesis
Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 2R01CA134777-06A1), $374,063USD, 04/01/2011 -- 01/31/2024
 
Targeting Novel Pathways in JMML
Kapur, Reuben
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 1R01HL146137-01), $534,541USD, 01/15/2019 -- 12/31/2022
2018
Role of p21 activated kinase in Leukemogenesis
Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA173852-05), $323,700USD, 05/01/2014 -- 04/30/2019
2017
HSC-Independent Mechanisms Underlying JMML
Kapur, Reuben and YODER, MERVIN C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA202296-02), $205,538USD, 07/01/2016 -- 06/30/2018
 
Role of p21 activated kinase in Leukemogenesis
Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA173852-04), $323,700USD, 05/01/2014 -- 04/30/2019
2016
Novel Mechanisms of C-Kit Regulation in Mast Cells
Kapur, Reuben
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 4R01HL077177-08), $390,000USD, 07/01/2004 -- 04/30/2017
 
Role of p21 activated kinase in Leukemogenesis
Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA173852-03), $323,700USD, 05/01/2014 -- 04/30/2019
2015
Novel Mechanisms of C-Kit Regulation in Mast Cells
Kapur, Reuben
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 5R01HL077177-07), $384,150USD, 07/01/2004 -- 04/30/2017
 
Role of p21 activated kinase in Leukemogenesis
Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA173852-02), $323,700USD, 05/01/2014 -- 04/30/2019
 
Role of Shp2 in FLT3-ITD-Induced Leukemogenesis
CHAN, REBECCA J and Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA134777-05), $319,550USD, 04/01/2011 -- 03/31/2017
2014
Novel Mechanisms of C-Kit Regulation in Mast Cells
Kapur, Reuben
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 5R01HL077177-06), $382,200USD, 07/01/2004 -- 04/30/2017
 
Role of p21 activated kinase in Leukemogenesis
Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA173852-01A1), $323,700USD, 05/01/2014 -- 04/30/2019
 
Role of Shp2 in FLT3-ITD-Induced Leukemogenesis
CHAN, REBECCA J and Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA134777-04), $309,964USD, 04/01/2011 -- 03/31/2016
2013
Novel Mechanisms of C-Kit Regulation in Mast Cells
Kapur, Reuben
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 2R01HL077177-05A1), $371,280USD, 07/01/2004 -- 04/30/2017
 
Role of Shp2 in FLT3-ITD-Induced Leukemogenesis
CHAN, REBECCA J and Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA134777-03), $300,377USD, 04/01/2011 -- 03/31/2016
 
Role of Vav and Rac in KIT oncogenesis
Kapur, Reuben
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 5R01HL081111-05), $362,855USD, 01/19/2009 -- 11/30/2014
2012
Role of Shp2 in FLT3-ITD-Induced Leukemogenesis
CHAN, REBECCA J and Kapur, Reuben
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA134777-02), $319,550USD, 04/01/2011 -- 03/31/2016